1. Home
  2. CNTA vs NTLA Comparison

CNTA vs NTLA Comparison

Compare CNTA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTA
  • NTLA
  • Stock Information
  • Founded
  • CNTA 2020
  • NTLA 2014
  • Country
  • CNTA United Kingdom
  • NTLA United States
  • Employees
  • CNTA N/A
  • NTLA N/A
  • Industry
  • CNTA Biotechnology: Pharmaceutical Preparations
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CNTA Health Care
  • NTLA Health Care
  • Exchange
  • CNTA Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • CNTA 2.0B
  • NTLA 1.4B
  • IPO Year
  • CNTA 2021
  • NTLA 2016
  • Fundamental
  • Price
  • CNTA $15.99
  • NTLA $16.06
  • Analyst Decision
  • CNTA Strong Buy
  • NTLA Buy
  • Analyst Count
  • CNTA 7
  • NTLA 17
  • Target Price
  • CNTA $23.14
  • NTLA $58.63
  • AVG Volume (30 Days)
  • CNTA 285.4K
  • NTLA 2.8M
  • Earning Date
  • CNTA 11-15-2024
  • NTLA 11-07-2024
  • Dividend Yield
  • CNTA N/A
  • NTLA N/A
  • EPS Growth
  • CNTA N/A
  • NTLA N/A
  • EPS
  • CNTA N/A
  • NTLA N/A
  • Revenue
  • CNTA $6,853,000.00
  • NTLA $45,967,000.00
  • Revenue This Year
  • CNTA N/A
  • NTLA $49.33
  • Revenue Next Year
  • CNTA N/A
  • NTLA $9.99
  • P/E Ratio
  • CNTA N/A
  • NTLA N/A
  • Revenue Growth
  • CNTA N/A
  • NTLA N/A
  • 52 Week Low
  • CNTA $5.58
  • NTLA $13.95
  • 52 Week High
  • CNTA $17.59
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • CNTA 55.33
  • NTLA 40.65
  • Support Level
  • CNTA $14.48
  • NTLA $14.55
  • Resistance Level
  • CNTA $15.64
  • NTLA $16.98
  • Average True Range (ATR)
  • CNTA 0.68
  • NTLA 1.01
  • MACD
  • CNTA -0.00
  • NTLA -0.14
  • Stochastic Oscillator
  • CNTA 75.88
  • NTLA 28.06

About CNTA Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: